Reports Q3 revenue $741k, consensus $500k. “Our Phase 2 B-SUPREME study of pevifoscorvir sodium is enrolling nicely, with subjects dosed across a number of countries, including the U.S., China, Hong Kong, and Canada,” stated Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive Officer of Aligos Therapeutics (ALGS). “We are pleased with the progress to date and look forward to interim readouts in 2026. Importantly, we look forward to sharing additional pevy data next week at AASLD’s The Liver Meeting. We maintain our enthusiasm regarding the potential for pevy as well as our entire development pipeline, including ALG-055009, which is in continued discussions with potential partners for obesity and MASH.”
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALGS:
- Aligos Therapeutics’ Promising Hepatitis B Study: A Potential Game-Changer?
- Aligos Therapeutics announces inducement grants under Nasdaq listing rule
- Aligos Therapeutics receives USAN council approval for pevifoscorvir sodium
- Positive Outlook on Aligos Therapeutics’ MASH Treatment Potential and Strategic Valuation
- Aligos Therapeutics’ Promising Drug Pipeline and Strategic Advancements Justify Buy Rating and $50 Price Target